A new scientific review is drawing renewed attention to plasminogen activator inhibitor-1 (PAI-1), a protein increasingly recognized for its role not only in blood clot regulation but also in the biological processes underlying aging and age-related disease. Researchers are actively exploring small-molecule inhibitors of PAI-1 as a potential therapeutic approach to slow aspects of physiological decline associated with aging.

PAI-1, encoded by the SERPINE1 gene, is the primary physiological inhibitor of tissue-type and urokinase-type plasminogen activators, placing it at the center of fibrinolysis and blood clot regulation. However, accumulating evidence suggests that its biological influence extends far beyond hemostasis. PAI-1 has been implicated in tissue remodeling, fibrosis, metabolic dysfunction, cancer progression, chronic inflammation, immune dysregulation, and the accumulation of senescent cells.

Of particular interest to aging research is the association between PAI-1 and the senescence-associated secretory phenotype (SASP)—a pro-inflammatory cellular state that contributes to tissue dysfunction over time. Scientists propose that PAI-1 may act as a central signaling node linking senescent cells, inflammatory pathways, impaired immune surveillance, and fibrotic remodeling of the extracellular matrix. In this emerging model, PAI-1 functions as a potential “immune-aging checkpoint,” reinforcing tissue deterioration and limiting regenerative capacity.

Evidence supporting the relevance of PAI-1 to aging includes rare human cases involving inherited loss-of-function mutations in the SERPINE1 gene. Individuals with reduced PAI-1 activity have been reported to exhibit extended lifespan, with some studies suggesting survival advantages of several years compared to population averages. While such findings are preliminary, they have strengthened interest in whether pharmacological inhibition of PAI-1 could mimic aspects of this protective genetic effect.

The review highlights a growing pipeline of structure-guided drug discovery efforts aimed at developing small-molecule PAI-1 inhibitors. Compounds such as TM5275, TM5441, TM5509, and TM5614 have been identified and evaluated in preclinical studies. Among these, TM5614 has emerged as a leading candidate due to its oral bioavailability and advancement into early clinical investigation.

Preclinical research suggests that PAI-1 inhibition may produce a range of beneficial biological effects, including anti-thrombotic, anti-fibrotic, anti-inflammatory, anti-senescent, and tumor microenvironment-modulating activity. These findings have motivated exploration of PAI-1 inhibitors in multiple disease contexts, including cancer, fibrotic disorders, immune-related conditions, and infectious disease complications.

Early clinical studies of TM5614 have examined its potential applications in chronic myeloid leukemia, immune checkpoint inhibitor–refractory malignant melanoma, non-small cell lung cancer, and COVID-19-associated pneumonia. While results remain preliminary, these investigations are helping to establish the safety profile and therapeutic potential of PAI-1 inhibition in humans.

Researchers caution that pharmacological inhibition of PAI-1 is unlikely to replicate the full biological effects seen in rare genetic loss-of-function cases. Drug-based inhibition is typically partial, time-limited, and subject to pharmacokinetic constraints. Nonetheless, such interventions are considered a practical step in translating genetic and mechanistic insights into clinically viable therapies.

The review concludes that targeting PAI-1 represents a promising but still early-stage strategy in the broader field of aging biology. Continued research is needed to clarify long-term safety, optimal dosing strategies, and the extent to which PAI-1 inhibition can meaningfully impact aging trajectories and age-associated disease burden.